https://biotechmorning.com/news/ai-scientist-builds-biotech-companies Biotech Morning en 2026-06-30T14:26:41.512Z The AI That Builds Biotech Companies While You Sleep https://biotechmorning.com/news/biocryst-shuts-down-internal-discovery Biotech Morning en 2026-06-30T14:25:46.513Z BioCryst Just Blew Up Its Own Lab https://biotechmorning.com/news/merck-kgaa-bio-techne-acquisition-cell-therapy Biotech Morning en 2026-06-30T14:24:53.763Z Merck KGaA Just Wrote an $11.3 Billion Check for the Cell Therapy Picks and Shovels https://biotechmorning.com/news/parabilis-medicines-record-biotech-ipo Biotech Morning en 2026-06-30T14:23:57.130Z The Biotech IPO That Just Dethroned Moderna https://biotechmorning.com/news/moderna-mrna-flu-vaccine-fda-panel-endorsement Biotech Morning en 2026-06-30T14:23:03.354Z Moderna's Flu Shot Just Cleared Its Biggest Hurdle. Now the Real Fight Begins. https://biotechmorning.com/news/enspryng-thyroid-eye-disease-at-home-injection Biotech Morning en 2026-06-30T14:22:08.996Z The Eye Disease Drug That Wants to Ditch the IV Pole https://biotechmorning.com/news/vistagen-anxiety-drug-phase-3-failures Biotech Morning en 2026-06-30T14:21:17.556Z Vistagen's Anxiety Drug Just Went 1-for-3 in Phase 3. Now What? https://biotechmorning.com/news/fda-running-on-fumes-biotech-paying-price Biotech Morning en 2026-06-30T14:20:19.552Z The FDA Is Running on Fumes, and Biotech Is Paying the Price https://biotechmorning.com/news/fda-precheck-pilot-manufacturing-reviews Biotech Morning en 2026-06-30T14:19:26.343Z The FDA Wants to Review Your Factory Before You Even Build It https://biotechmorning.com/news/boulevard-bio-1-6-billion-trispecific-tce-deal Biotech Morning en 2026-06-30T14:18:41.616Z A $1.6 Billion Bet on a Drug That Doesn't Exist Yet https://biotechmorning.com/news/stealth-antibody-vir-astellas-prostate-cancer-deal Biotech Morning en 2026-06-29T14:27:45.289Z The Stealth Antibody That Fooled Its Way Into a $1.7B Prostate Cancer Deal https://biotechmorning.com/news/novo-nordisk-cagrisema-loses-to-zepbound-3 Biotech Morning en 2026-06-29T14:26:53.981Z Novo Nordisk Just Lost the Obesity Drug Super Bowl https://biotechmorning.com/news/adhd-drug-centanafadine-anxiety-otsuka-phase-3b Biotech Morning en 2026-06-29T14:26:01.104Z The ADHD Drug That Might Actually Help Your Anxiety Too https://biotechmorning.com/news/astrazeneca-strensiq-successor-mixed-phase-3-results Biotech Morning en 2026-06-29T14:25:02.913Z AstraZeneca's Strensiq Sequel Aced the Kids' Test. Then Came the Adults. https://biotechmorning.com/news/novartis-qeq278-zero-responses-30-patients Biotech Morning en 2026-06-29T14:24:00.305Z Novartis Tested a Cancer Drug on 30 Patients. None of Them Responded. https://biotechmorning.com/news/lilly-zepbound-vial-pricing-glp1-price-war Biotech Morning en 2026-06-29T14:23:11.486Z Lilly's Quiet Move to Win the GLP-1 Price War https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-elevidys Biotech Morning en 2026-06-29T14:22:08.447Z Sarepta's Worst Week: A Black Box Warning and 500 Pink Slips https://biotechmorning.com/news/ipsen-kartos-myelofibrosis-deal Biotech Morning en 2026-06-29T14:21:16.154Z Ipsen Just Bet $1.75 Billion on a Drug That Doesn't Have Data Yet